博雅生物
(300294)
| 流通市值：133.62亿 | | | 总市值：158.18亿 |
| 流通股本：4.26亿 | | | 总股本：5.04亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 1,860,435,345.29 | 1,961,478,737.03 | 1,342,767,444.78 | 1,941,279,499.62 |
| 应收票据及应收账款 | 240,863,138.38 | 209,836,815.66 | 258,064,802.5 | 457,521,795.27 |
| 应收账款 | 240,863,138.38 | 209,836,815.66 | 258,064,802.5 | 457,521,795.27 |
| 应收款项融资 | 77,354,865.01 | 66,078,942.62 | 73,521,779.99 | 99,123,893.65 |
| 预付款项 | 2,621,056.4 | 4,667,704.75 | 3,431,720.57 | 9,286,251.49 |
| 其他应收款合计 | 154,410,294.22 | 264,403,475.84 | 354,264,211.27 | 50,513,366.23 |
| 存货 | 566,513,200.98 | 556,940,121.4 | 579,701,942.68 | 581,972,654.07 |
| 其他流动资产 | 2,610,401.63 | 1,766,406.94 | 638,467.25 | 1,244,617.95 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 6,612,770,411.54 | 6,427,633,042.37 | 6,379,271,809.29 | 6,188,780,388.88 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 92,371,689.71 | 100,394,389.71 | 111,835,585.86 | 121,088,345.32 |
| 投资性房地产 | 636,418.7 | 649,007.63 | 661,760.64 | 674,523.27 |
| 固定资产 | 619,746,404.43 | 634,234,017.87 | 647,160,424.65 | 617,951,502.9 |
| 在建工程 | 40,975,483.83 | 39,936,463.03 | 61,781,327.3 | 90,414,175.66 |
| 使用权资产 | 2,039,060.2 | 2,448,954.7 | 2,870,212.25 | 11,583,653.43 |
| 无形资产 | 265,805,718.83 | 269,314,822.71 | 313,767,033.2 | 318,892,912.3 |
| 开发支出 | 55,927,561.91 | 53,220,110.15 | 54,494,597.21 | 47,100,400.31 |
| 商誉 | 72,612,799.46 | 72,612,799.46 | 497,773,843.46 | 663,841,978.78 |
| 长期待摊费用 | 33,009,917.33 | 34,930,845.93 | 50,530,411.52 | 41,140,650.16 |
| 递延所得税资产 | 50,008,208.14 | 47,343,876.52 | 42,555,956.66 | 45,738,463.6 |
| 其他非流动资产 | 146,946,796.8 | 146,181,971.81 | 20,255,956.48 | 20,368,170.52 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,380,080,059.34 | 1,401,267,259.52 | 1,803,687,109.23 | 1,978,794,776.25 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 7,992,850,470.88 | 7,828,900,301.89 | 8,182,958,918.52 | 8,167,575,165.13 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 115,834,621.51 | 126,349,963.93 | 140,921,109.93 | 229,510,401.35 |
| 其中：应付票据 | 48,194,526.67 | 49,744,528.62 | 38,034,903.87 | 41,357,151.92 |
| 应付账款 | 67,640,094.84 | 76,605,435.31 | 102,886,206.06 | 188,153,249.43 |
| 预收款项 | - | 110,564.57 | - | 2,142.82 |
| 合同负债 | 8,145,843.27 | 12,205,635.32 | 5,857,865.42 | 8,175,925.42 |
| 应付职工薪酬 | 63,674,500.42 | 82,670,811.91 | 89,605,772 | 100,081,301.89 |
| 应交税费 | 41,426,245.67 | 24,469,312.28 | 46,733,835.27 | 36,359,625.03 |
| 其他应付款合计 | 238,762,851.41 | 208,650,030.21 | 271,152,305.95 | 245,189,769.46 |
| 一年内到期的非流动负债 | 871,310.68 | 907,054.3 | 777,865.48 | 2,552,101.25 |
| 其他流动负债 | 992,101.63 | 1,083,642.25 | 1,221,444.1 | 1,639,872.82 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 469,707,474.59 | 456,447,014.77 | 556,270,198.15 | 623,511,140.04 |
| 非流动负债: | | | | |
| 长期借款 | 22,145,000 | 22,145,000 | 22,145,000 | 22,145,000 |
| 租赁负债 | 1,404,239.01 | 1,402,741.71 | 1,618,663.94 | 9,011,285.19 |
| 递延收益 | 22,515,031.62 | 23,517,680.64 | 24,988,079.67 | 25,020,478.7 |
| 递延所得税负债 | 4,492,383.86 | 4,562,365.4 | 5,225,396.92 | 5,336,139.55 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 50,556,654.49 | 51,627,787.75 | 53,977,140.53 | 61,512,903.44 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 520,264,129.08 | 508,074,802.52 | 610,247,338.68 | 685,024,043.48 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 504,248,738 | 504,248,738 | 504,248,738 | 504,248,738 |
| 资本公积 | 4,062,997,016.14 | 4,062,997,016.14 | 4,068,346,136.31 | 4,065,496,771.47 |
| 盈余公积 | 252,124,369 | 252,124,369 | 252,124,369 | 252,124,369 |
| 未分配利润 | 2,652,405,341.45 | 2,500,380,454.64 | 2,726,982,659.42 | 2,588,833,341.73 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 7,471,775,464.59 | 7,319,750,577.78 | 7,551,701,902.73 | 7,410,703,220.2 |
| 少数股东权益 | 810,877.21 | 1,074,921.59 | 21,009,677.11 | 71,847,901.45 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 7,472,586,341.8 | 7,320,825,499.37 | 7,572,711,579.84 | 7,482,551,121.65 |
| 负债和股东权益合计 | 7,992,850,470.88 | 7,828,900,301.89 | 8,182,958,918.52 | 8,167,575,165.13 |
| 公告日期 | 2024-04-24 | 2024-03-23 | 2023-10-26 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |